Beating Back Cancer

You ARE what you eat. June 2010 E-zine on eating against cancer.

Scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers, they say. The study, detailed in the June 10 issue of the journal Blood, showed in animal models the new technique was successful in drastically reducing B cell lymphoma, a cancer of immune molecules called B cells.

MISSISSAUGA, ON, May 26 /CNW/ - Lymphoma Foundation Canada (LFC) applauds Ontario's recent decision to publicly fund Rituxan (rituximab) in combination with Fludarabine-based chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). "Lymphoma Foundation Canada applauds the Ontario government for making Rituxan publicly accessible to chronic lymphocytic leukemia patients," said Sue Robson, executive director, Lymphoma Foundation Canada. "Rituxan is the standard of care for CLL, and this news provides hope for Ontarians living with this disease."

Exactly what it says, and an excellent, user-friendly resource.

OncoLink's blogs gives our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other. Join the Conversation!

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus (HBV) and progression to cancers other than hepatocellular carcinoma. The study found that a higher risk of Non-Hodgkin Lymphoma (NHL) and Cholangiocarcinoma was associated with HBV infection in the presence of higher levels of viral replication.

Findings published in today's issue of Cancer Cell show that an experimental compound designed by a team of researchers from Weill Cornell Medical College, the University of Maryland and the Ontario Cancer Center at the University of Toronto may effectively block the cancer-causing actions of BCL6 by attaching to a critical "hot spot" on its surface, thus killing off the cancer cells.